Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.2 - $4.98 $1,625 - $3,680
-739 Reduced 7.09%
9,686 $22,000
Q1 2024

May 10, 2024

SELL
$2.1 - $4.83 $24,534 - $56,428
-11,683 Reduced 52.85%
10,425 $45,000
Q4 2023

Feb 12, 2024

BUY
$1.12 - $3.73 $3,389 - $11,286
3,026 Added 15.86%
22,108 $67,000
Q3 2023

Nov 13, 2023

BUY
$1.22 - $2.67 $13,075 - $28,617
10,718 Added 128.14%
19,082 $27,000
Q2 2023

Aug 10, 2023

BUY
$2.46 - $3.14 $8,784 - $11,212
3,571 Added 74.5%
8,364 $20,000
Q1 2023

May 12, 2023

BUY
$2.57 - $8.16 $5,985 - $19,004
2,329 Added 94.52%
4,793 $12,000
Q4 2022

Feb 10, 2023

SELL
$5.19 - $13.5 $30,947 - $80,500
-5,963 Reduced 70.76%
2,464 $13,000
Q3 2022

Nov 14, 2022

BUY
$5.17 - $16.99 $20,266 - $66,600
3,920 Added 86.98%
8,427 $105,000
Q2 2022

Aug 10, 2022

BUY
$4.04 - $8.51 $14,539 - $30,627
3,599 Added 396.37%
4,507 $23,000
Q1 2022

May 04, 2022

SELL
$7.6 - $11.02 $5,532 - $8,022
-728 Reduced 44.5%
908 $193,000
Q3 2021

Nov 05, 2021

SELL
$13.16 - $22.47 $16,581 - $28,312
-1,260 Reduced 43.51%
1,636 $21,000
Q2 2021

Aug 02, 2021

SELL
$19.57 - $26.32 $146,892 - $197,557
-7,506 Reduced 72.16%
2,896 $64,000
Q1 2021

May 13, 2021

BUY
$17.58 - $32.59 $120,264 - $222,948
6,841 Added 192.11%
10,402 $250,000
Q4 2020

Feb 10, 2021

BUY
$10.99 - $20.4 $39,135 - $72,644
3,561 New
3,561 $64,000
Q3 2020

Nov 12, 2020

SELL
$11.55 - $23.75 $7,507 - $15,437
-650 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$9.57 - $24.37 $29,226 - $74,425
-3,054 Reduced 82.45%
650 $15,000
Q1 2020

May 18, 2020

BUY
$9.07 - $26.32 $33,595 - $97,489
3,704 New
3,704 $41,000

Others Institutions Holding GTHX

About G1 Therapeutics, Inc.


  • Ticker GTHX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,746,800
  • Market Cap $306M
  • Description
  • G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...
More about GTHX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.